IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Cantaganie Flohr, et al

Examiner:

Not Yet Assigned

Art Unit:

Not Yet Assigned

Application No.: 10/613,482

Filed: **July 3, 2003**

Title: Pyrazoloisoquinoline Derivatives For

Inhibiting NFkappaB-Inducing Kinase

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Mail Stop Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

 \boxtimes This Information Disclosure Statement is filed within the period set forth in §1.97(b) (a) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

(b)	This	s Information Disclosure Statement is filed after the period set forth in 37 C.F.R.
	1.97	(b), but is believed to be filed before the mailing date of a final action under §1.113
	or a	notice of allowance under §1.311, whichever occurs first.
	(1)	The undersigned attorney certifies that each item of information contained in this
		Information Disclosure Statement was cited in a communication from a foreign
		patent office in a counterpart foreign application not more than three months prior
		to the filing of this statement;
	(2)	The undersigned attorney certifies that no item of information contained in this
		Information Disclosure Statement was cited in a communication from a foreign
		patent office in a counterpart foreign application or, to the knowledge of the
		undersigned attorney after making reasonable inquiry, was known to any
		individual designated in §1.56(c) more than three months prior to the filing of this
		statement; or
	(3)	This Information Disclosure Statement is accompanied by a transmittal letter in
		which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is
		authorized.
		Respectfully submitted,
		Bolonam Guer
		Balaram Gupta, Reg. No. 40,009
•		Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3364
Telefax (908) 231-2626

Aventis Docket No. DEAV2002/0045 US NP

, -	.	sign (+) inside this box			Patent and Tradema	PTO/SB/08A (10-96) roved for use through 10/31/99. OMB 0651-0031 ark Office: U.S. DEPARTMENT OF COMMERCE n unless it contains a valid OMB control number.
APR 15	Substitu	ite for form 1449A/PTO			Co	omplete if Known
	/3				Application Number	10/613,482
x	WIF	ORMATION	DI	SCLOSURE	Filing Date	07-03-2003
Ex.	STATEMENT BY APPLICANT				First Named Inventor	STEFANIE FLOHR, ET AL
QDEM					Group Art Unit	
		(use as many shee	ets as	s necessary)	Examiner Name	
	Sheet	1	of	2	Attorney Docket Number	DEAV2002/0045 - US - NP

	U.S. PATENT DOCUMENTS							
Examiner nitials*	Cite No.1	U.S. Paten	Kind Code ² (if known)	Name of Patentee or Applicant	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		4,748,246		SKOTNICKI, ET AL	05-31-1988			

Name of Patentee or licant of Cited Document MM-DD-YYYY Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
licant of Cited Document MM-DD-YYYY Passages or Relevant Figures Appear T6
ET AL 03-27-2003

$\overline{}$		
Examiner	Date	
Signature	Considered	

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	PTO	/SB/08B	(10-9
Annoved for use through	10/31/99	OMB 065	ำ_กกจ

DEAV2002/0045 - US - NP

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Please type a plus sign (+) inside this box ->

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449B/PTO **Application Number** 10/613,482 INFORMATION DISCLOSURE **Filing Date** 07-03-2003 STATEMENT BY APPLICANT STEFANIE FLOHR, ET AL First Named Inventor Group Art Unit (use as many sheets as necessary) **Examiner Name** Sheet of 2 Attorney Docket Number

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²			
		LUCIA CECCHI et al., Synthesis of 1,5-Diaryl-3-Methyl-1 H-pyrazolo[4,5-c] Isoquinolines And Studies of Binding to Specific Peripheral Benzodiazepine Binding Sites, Journal of Pharmaceutical Sciences (1989, pp. 437-442, Volume 78, No. 6)				
Examine		Date				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.